President Trump initiated multiple programs aimed at reducing prescription drug costs, including demanding voluntary price reductions from drugmakers, negotiating "most favored nation" pricing for Medicaid, and launching the TrumpRx website for cash-paying patients. While some specific drugs, like certain fertility treatments and weight-loss medications, saw price drops on the TrumpRx platform, many others, including over 1,000 brand-name drugs, experienced price increases in January 2026, a trend observed as "business as usual" by industry analysts. A significant win for patients, though largely continuing a Biden administration program, is Medicare's negotiation of prices for high-cost drugs, resulting in substantial savings and a cap on out-of-pocket expenses for Medicare Part D enrollees. However, the effectiveness of Trump's individual initiatives for the broader population is debated due to their limited scope, opacity, and the continued complexities of patent law hindering generic and biosimilar competition.